Daniel Patton, PhD

Mozart Therapeutics
Seattle, WA, United States

Presentation(s):

• 0089: Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases

  Sunday, November 12, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.